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Abstract 
Background: Myocardial infarction (MI) is a major cause of heart failure. The carboxypeptidase cathepsin A is a novel 
target in the treatment of cardiac failure. We aim to show that recently developed inhibitors of the protease cathepsin 
A attenuate post-MI heart failure.
Methods: Mice were subjected to permanent left anterior descending artery (LAD) ligation or sham operation. 24 h 
post–surgery, LAD-ligated animals were treated with daily doses of the cathepsin A inhibitor SAR1 or placebo. After 
4 weeks, the three groups (sham, MI-placebo, MI-SAR1) were evaluated.
Results: Compared to sham-operated animals, placebo-treated mice showed significantly impaired cardiac function 
and increased plasma BNP levels. Cathepsin A inhibition prevented the increase of plasma BNP levels and displayed a 
trend towards improved cardiac functionality. Proteomic profiling was performed for the three groups (sham, MI-
placebo, MI-SAR1). More than 100 proteins were significantly altered in placebo-treated LAD ligation compared to the 
sham operation, including known markers of cardiac failure as well as extracellular/matricellular proteins. This ensem-
ble constitutes a proteome fingerprint of myocardial infarction induced by LAD ligation in mice. Cathepsin A inhibitor 
treatment normalized the marked increase of the muscle stress marker CA3 as well as of Igγ 2b and fatty acid syn-
thase. For numerous further proteins, cathepsin A inhibition partially dampened the LAD ligation-induced proteome 
alterations.
Conclusions: Our proteomic and functional data suggest that cathepsin A inhibition has cardioprotective properties 
and support a beneficial effect of cathepsin A inhibition in the treatment of heart failure after myocardial infarction.
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Background
Cathepsin A is a multifunctional protein with diverse 
sub-cellular localizations. Mostly found in the lyso-
some, cathepsin A is also present at the cell surface and 
secreted outside the cell [1, 2]. Cathepsin A is widely 
known for forming a multi-protein complex with lyso-
somal neuraminidase and β-galactosidase, which pro-
tects β-galactosidase from proteolytic degradation and 
activates neuraminidase. Genetic deficiency of the cath-
epsin A protein leads to reduced levels of β-galactosidase 
and results in the lysosomal storage disease galactosiali-
dosis [1, 2].
Enzymatically, cathepsin A acts as a carboxypeptidase 
in the lysosome. In mice, expression of catalytically inac-
tive cathepsin A in lieu of the wild-type variant does not 
cause galactosialidosis, highlighting that cathepsin A 
enzymatic activity is not linked to its role in protecting 
β-galactosidase and neuraminidase [3]. In the same pub-
lication the authors also report an impact of loss of cath-
epsin A enzymatic activity on elastic fiber formation and 
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involved in the processing of vascular peptides, such as 
endothelin-1, bradykinin and angiotensin [4].
Cathepsin A has recently gained attention as a promis-
ing target for the treatment of heart failure [5]. Cathep-
sin A mRNA expression is up-regulated in infarcted rat 
and mouse tissue [6, 7] and its role in the regulation of 
local bradykinin was demonstrated in animal models of 
hypertension [8]. Orally available, selective cathepsin A 
inhibitors have been recently presented, which are based 
on β-amino acid derivatives [8]. The new inhibitors have 
beneficial pharmacokinetic profiles and showed remark-
able protection in rat models of cardiac hypertrophy and 
of atrial fibrillation [8]. One of these inhibitors, named 
SAR1 (refer to as compound 2a in the work of Ruf et al. 
[8], IC50 =  26 nM), successfully passed through phase I 
clinical trials showing favorable safety profile in healthy 
young and elderly human subjects [9].
In the last decade, the etiology of heart failure has 
shifted from hypertension and valvular disease as most 
common causes to heart failure following myocardial 
infarction (MI) [10]. MI is defined as a pathological event 
involving myocardial cell necrosis due to significant and 
sustained ischemia [11]. MI results from either coro-
nary heart disease, implying obstruction of blood flow 
due to plaques in the coronary arteries or, much less fre-
quently, to other obstructing mechanisms (e.g. spasm of 
plaque-free arteries) [11]. In response to MI the left ven-
tricle undergoes profound alterations of its architecture, 
including interstitial fibrosis, remodeling in the non-
infarcted myocardium, and ventricular hypertrophy [12].
Protease inhibition therapy is prominently employed in 
the area of cardiovascular diseases [13]. Besides anticoag-
ulants, this includes modulators of the renin-angiotensin 
system, which generally yield vasodilatory effects. In the 
treatment of post-MI heart failure, vasodilation reduces 
pre- and afterload and thus displays a cardioprotective 
effect and reduced cardiac remodeling.
In the present report, we probe the effect of cathep-
sin A inhibition in a mouse model of LAD ligation using 
both functional and proteomic analyses.
Methods
Animals
Six to seven week old male C57BL/6 mice weighing 
19−25  g were purchased from Charles River Laborato-
ries. Twelve weeks old Wistar rats weighing 250–300  g 
were purchased from Harlan. Animals were housed in 
an air-conditioned room with a 12  h dark/light cycle 
and received standard mouse chow with free access to 
tap water. They were allowed 7 days to adjust to the new 
environment before starting the experiments. All animal 
studies conformed to the German law for the protec-
tion of animal guidelines and the guide for the care and 
use of laboratory animals published by the US National 
Institutes of Health (NIH Publications No 85–23, revised 
1996) as well as to Sanofi-Aventis Ethical Committee 
guidelines.
Compound characteristics
SAR1 was synthesized in the chemical department of 
Sanofi. SAR1 ((S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-
1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic 
acid) is a new orally active cathepsin A inhibitor previ-
ously described as compound 2a by Ruf et al. [8].
Surgical induction of myocardial infarction
Study animals were randomized to MI versus sham oper-
ation. Mice were anaesthetized with 0.1  ml/10  g body 
weight i.p. of a mixture of ketamine (100  mg/ml), xyla-
zine (20  mg/ml) and atropine (0.5  mg/ml). They were 
placed on a heated operating table and ventilated at a 
tidal volume of 7 µl/g body weight. The body temperature 
was controlled by a rectal probe and maintained at 37 °C. 
A left thoracotomy was performed via the third inter-
costal space. MI was induced by placing a 7/0 silk suture 
around the left anterior descending coronary artery near 
the atrial auricle. For animals undergoing a sham opera-
tion only the chest cavity was opened without further 
surgical procedures. The lungs were inflated by increas-
ing positive end-expiratory pressure and the thoracotomy 
site was closed. Animals were allowed to recover and 
treated with 0.1  mg/10  g body weight buprenorphine 
(0.3  mg/ml) by subcutaneous injection for post-opera-
tive analgesia. Mice were then randomized to placebo or 
SAR1 (100 mg/kg in chow). Treatment started 1 day after 
LAD ligation and lasted for 4 weeks. In the SAR1 group 
fourteen animals died during the 1st week in contrast to 
eight in the placebo group. No further deaths occurred 
between weeks two and four in both groups. The differ-
ence in mortality under SAR1 treatment did not reach 
significance (p value  >0.08, Mantel-Cox log-rank test). 
The final sample size at the end of the study for each 
group was the following: sham (n  =  10), MI-placebo 
(n = 15), MI-SAR1 (n = 10). For determination of infarct 
size hearts were cut open at the end of the study, pho-
tographed and digitized. Images were analyzed for total 
and the more lucid infarcted area with the Explora Nova 
image analysis software Morpho Expert (La Rochelle, 
France) using a Leica- macrosetup.
Surgery in rats was performed in a similar way as 
described before [14]. They were randomized to placebo 
or SAR1 (3, 10 and 30  mg/kg, p.o.). Treatment started 
1  day after LAD ligation and lasted for 7  days. Sample 
size for each group was the following: sham (n = 10), MI-
placebo (n = 13), MI-SAR1 3 mg/kg (n = 11), MI-SAR1 
10 mg/kg (n = 11), MI-SAR1 30 mg/kg (n = 11).
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Hemodynamic evaluation
For the assessment of pressure–volume relationships, 
mice were anesthetized with 2  % Isoflurane. Respira-
tion was controlled through a tracheotomy cannula, and 
animals were mechanically ventilated (Minivent, Hugo 
Sachs) at 140 breaths/min and a tidal volume of 7 µl room 
air/g BW. Physiological temperature was maintained with 
a heated operating table with rectal probe. The left ven-
tricle was catheterized retrogradely via the right carotid 
artery using a 1.4 F impedance-micromanometer tip 
catheter (Millar Instruments, Houston, TX, USA). Pres-
sure–volume signals were recorded at steady state and 
during transient preload reduction achieved by vena 
cava inferior occlusion. Artificial ventilation was stopped 
during sampling of approximately ten cardiac cycles for 
analysis of pressure–volume measurement. Data were 
digitalized with a sampling rate of 1000 Hz and recorded 
using specialized software (HEM 3.5, Notocord, France). 
For subsequent analysis of pressure–volume loops, Noto-
cord and Excel software was used.
In rats hemodynamic parameters were measured in 
anaesthetized animals using Millar Tip catheters (Mil-
lar Instruments Inc, Houston, USA) introduced from the 
right arteria carotis and advanced into the left ventricle.
Plasma BNP
Plasma BNP32 was determined with commercially avail-
able ELISAs (RayBiotech, Phoenix Pharmaceuticals Inc.)
Preparation of tissue samples for proteomic analysis
Snap frozen fresh mouse left ventricles (50–100  mg) 
were lysed in 500 µl of homogenization buffer (100 mM 
Na-acetate, 5 mM EDTA, 1 mM dithiothreitol, 0.01 mM 
trans-epoxysuccinyl-L-leucylamido (4-guanidino)butane 
(E64), 1  mM phenyl-methanesulfonyl fluoride, 0.05  % 
Brij, pH 5.5) using an Ultra-Turrax and centrifuged at 
1000g for 15  min at 4  °C. Protein concentrations were 
determined via BCA protein assay kit (Thermo scientific).
Quantitative proteome comparison
For proteome comparison, left ventricles from sham 
operated mice (sham) and mice which underwent left 
coronary artery ligation treated with placebo or SAR1 
were prepared as described above. Preparation of mass 
spectrometry samples was performed as described pre-
viously, including stable isotope labeling with either for-
maldehyde light [d(0)12 C], medium [d(2)12 C] or heavy 
[d(2)13 C] for quantitative comparison and pre-fraction-
ation via strong cation exchange chromatography [15]. 
LC–MS/MS analysis is described in the corresponding 
section. MS files were analyzed by MaxQuant version 
1.3.0.5 with the Uniprot mouse database downloaded 
on October 2011, counting 44819 entries. MaxQuant 
analysis included an initial search with a precursor mass 
tolerance of 20 ppm for mass recalibration. In the main 
Andromeda search precursor mass and fragment mass 
were searched with initial mass tolerance of 6 ppm and 
0.5 Da respectively. The search included variable modifi-
cations of methionine oxidation and N-terminal acetyla-
tion, and fixed modification of carbamidomethyl cysteine. 
Minimal peptide length was set to seven amino acids and 
a zero missed cleavages were allowed. The false discovery 
rate (FDR) was set to 0.05 for peptide and protein identi-
fications; however we only considered proteins that were 
independently identified in at least three replicates. For 
comparison between samples we used a labeling scheme 
based on multiplicity three: dimethLys0/dimethNter0 
(light label); dimethLys4/dimethNter4 (medium label); 
dimethLys8/dimethNter8 (heavy label). A minimum of 
two ratio counts was used to determine the normalized 
protein intensity. Protein table were filtered to eliminate 
the identifications from the reverse database, and com-
mon contaminants.
LC–MS/MS analysis
Analysis was performed on an Orbitrap XL (Thermo sci-
entific) mass spectrometer that was coupled to an Ulti-
mate 3000 micro pump (Thermo scientific). Buffer A 
was 0.5 % acetic acid, buffer B 0.5 % acetic acid in 80 % 
acetonitrile (HPLC grade). Liquid phases were applied at 
a flow rate of 300 nl/min with an increasing gradient of 
organic solvent for peptide separation. Reprosil-Pur 120 
ODS-3 (Dr. Maisch, Ammerbuch, Germany) was used 
to pack column tips of 75 µm inner diameter and 11 cm 
length. The MS was operated in data dependent mode 
and each MS scan was followed by a maximum of five 
MS/MS scans.
Western blot
30 μg of heart tissue lysate were loaded on to 12 % SDS–
polyacrylamide gels. GAPDH served as an internal load-
ing control. After electrophoretic separation, proteins 
were transferred on polyvinylidene fluoride membranes 
using a semidry blot system (Bio-Rad, Munich, Ger-
many). After blocking, the membranes were exposed 
to the primary antibodies (GAPDH, 1:1000; carbonic 
anhydrase 3, 1:200; periostin, 1:500; troponin T, 1:1000; 
cytoglobin, 1:100) overnight at 4  °C. After washing, the 
membranes were incubated for 2  h with the second-
ary antibody. The membranes were washed and devel-
oped with the West Pico Chemiluminescent substrate 
(Pierce). Peroxidase activity was detected with a Lumi-
Imager device (Roche Applied Science, Mannheim, Ger-
many). The primary antibodies were purchased from 
Abcam (Cambridge, MA) (GAPDH: Cat.No. Ab9484), 
Santa Cruz Biotechnology (Santa Cruz, CA) (carbonic 
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anhydrase 3, Cat.No. Sc-50714; cytoglobin, Cat.No. 
Sc-66855), R&D Systems (Minneapolis, MN) (periostin: 
Cat. No. AF2955), Sigma-Aldrich (St. Louis, MO) (tro-
ponin T: Cat.No. SAB2502131). Western blots were 
quantified using the Fusioncapt advance software (Vilber 
Lourmat, Eberhardzell, Germany).
Cell culture
H9C2 rat cardiac myoblasts were purchased from ATCC 
(Cat.No. CRL-1446) and cultured in Dulbecco’s modified 
eagle medium (DMEM; PAN) supplemented with 10  % 
fetal calf serum (FCS; PAN), 1  % non-essential amino 
acids, 1  % MEM vitamins, 1  % penicillin/streptomycin 
at 37 °C in humidified air containing 5 % CO2. To mimic 
ischemia, cell were grown to 70  % confluency, washed 
three times with PBS and incubated in DMEM serum 
free supplied with SAR1 or DMSO for 24 h in a special 
incubation bag containing Anaerocult® A mini (Merck, 
Darmstadt, Germany), a chemical mixture that com-
pletely binds oxygen, creating an oxygen-free environ-
ment. The bag was sealed and severe hypoxia (<0.5 % O2) 
was assessed by color change of a test strip (Anaerotest, 
Merck) from blue to white within the first 90 min of incu-
bation [16, 17]. Human umbilical vein endothelial cells 
(HUVECs) were kindly provided by Dr. Jennifer Esser. 
Cells were cultured in enhanced endothelial cell growth 
medium (PELOBiotech GmbH, Martinsried, Germany) 
and used for angiogenesis assays.
Cell‑based assays
Caspase-3 activity was determined using a caspase-3 
activity assay kit (Enzo Life Sciences, Lörrach, Germany, 
Cat.No. ALX-260-031). Following the manufacturer’s 
protocol, cell lysates were incubated with reaction buffer 
and caspase-3 substrate Ac-DEVD-AMC for 10  min at 
37 °C. Fluorescence was measured using a TECAN Infi-
nite M200 microplate reader with excitation and emis-
sion wavelengths of 360 and 440 nm, respectively. FACS 
analysis using PI and YO-PRO®-1 (Invitrogen, Cat.No. 
V13243) was performed on cells plated in 6-well plates 
at 80,000 cells/well according to manufacturer’s instruc-
tions. Fluorescence intensity was measured by flow 
cytometry (FACScalibur, Fortessa) and evaluated with 
FlowJo (Tree Star, Inc.). The data were recorded for a 
total of 15,000 events per sample.
Statistical analysis
One-way Anova tests were applied separately to compare 
groups in the mice study. In the rat study, one-way Anova 
tests were applied to compare infarcted animals under 
placebo treatment to sham operated animals. Compari-
son of the different dosages of SAR1 with placebo was 
done by one-way analysis of variance followed by Tukey’s 
multiple comparison test. For proteomics and cell-based 
assays, statistical differences were calculated using Stu-
dent’s two-sided t test. Significance was set to p values 
<0.05. Data are expressed as mean  ±  SEM. Statistical 
analysis was performed using GraphPad version 6.07 for 
Windows (GraphPad Software, San Diego, CA).
Results and discussion
Survival and left ventricular weights upon cathepsin a 
inhibition in the MI model
To determine the effect of SAR1 on chronic heart fail-
ure, we used a mouse model of MI induced by perma-
nent LAD ligation. Three groups were investigated: (1) a 
sham control group (receiving only a left thoracotomy) 
(n = 10); (2) a placebo-treated MI group (n = 15); (3) MI 
group given the cathepsin A inhibitor SAR1 daily start-
ing one day after operation (100 mg/kg) (n = 10) (Fig. 1). 
Data for the left ventricular (LV) and body weights were 
determined 4 weeks after operation on the day of hemo-
dynamic measurements. The placebo group showed a sig-
nificant increase in LV mass/body mass ratio compared 
to the sham group (Fig.  2), as it is commonly observed 
in the permanent LAD ligation model of MI [18]. The 
increase in LV mass/body mass ratio was not affected by 
Fig. 1 Experimental design of the study. Sham operation or 
permanent LAD ligation were performed in mice. LAD ligation was 
either treated with placebo or with the cathepsin A inhibitor SAR1. 
After 28 days cardiac functionality was evaluated and a quantitative 
proteome study was conducted
(see figure on next page.) 
Fig. 2 Functional parameters in the murine MI model. Cardiac parameters were assessed 4 weeks after permanent ligation of the LAD. Three 
groups have been compared: sham (n = 10), MI-placebo (n = 15), MI-SAR1 (n = 10). Results are expressed as mean ± SEM. Differences significant at 
p < 0.05 are marked with an asterisk (*). LVESV left ventricular end-systolic volume, LVEDV left ventricular end-diastolic volume, LVEDP left ventricular 
end-diastolic pressure, CO cardiac output, EF ejection fraction, SV stroke volume, MAP mean arterial pressure, HR heart rate, dP/dt peak positive or 
negative first derivative of LV pressure, BNP plasma brain natriuretic peptide
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SAR1 treatment (Fig. 2). Infarct sizes ranged between 25 
and 30 % among mice and were not significantly different 
between placebo and SAR1-treated animals.
Cardiac functionality upon cathepsin a inhibition in the MI 
model
Next, we assessed how cathepsin A inhibition affects 
cardiac functionality compared to placebo treatment in 
the murine MI model. As expected, placebo treated ani-
mals developed severely impaired cardiac function after 
4  weeks of permanent LAD ligation (Fig.  2). These ani-
mals displayed hallmark features of post-MI heart failure, 
including increased left ventricular end systolic volume 
(LVESV) together with increased left ventricular end 
diastolic volume (LVEDV) and—pressure (LVEDP). Con-
sequently, cardiac output (CO) and ejection fraction (EF) 
were severely decreased. Mean arterial pressure (MAP) 
and heart rate (HR) were not affected by placebo-treated 
permanent LAD ligation. In line with limited cardiac 
functionality, dP/dt values were severely impaired; this is 
also reflected by an increased Tau-weiss value.
Cathepsin A inhibition dampened the increase of 
LVESV and LVEDP as compared to placebo treatment 
(Fig.  2), although not meeting statistical significance 
(One-way Anova test). Its effect on LVEDV was less 
pronounced. Similarly, cathepsin A inhibition (as com-
pared to placebo treatment) displayed a trend towards a 
protective effect concerning cardiac output (CO), ejec-
tion fraction (EF) and stroke volume (SV). However, the 
difference between placebo-treated and SAR1-treated 
animals did not reach statistical significance (One-way 
anova test). The same picture emerges for dP/dt and Tau-
weiss values. In an independent experimental setup, we 
demonstrated dose-dependent improvement of cardiac 
functionality by SAR1 in a rat model of permanent LAD 
ligation (Additional file 1).
Plasma brain natriuretic peptide (BNP) is considered 
a gold standard biomarker in determining the severity 
and prognosis of heart failure [19, 20]. We probed BNP 
plasma levels to monitor the progression of LAD liga-
tion-induced cardiac failure (Fig.  2). Placebo treatment 
yielded elevated BNP titers post—MI. SAR1 treatment 
significantly rescued this increase and yielded BNP levels 
that are within the range of sham-operated animals.
In summary, our data suggest that cathepsin A inhibi-
tion by SAR1 may contribute to improved cardiac per-
formance in the rodent permanent LAD ligation model 
systems.
Cathepsin A inhibition partially rescues the proteome 
alterations associated with permanent LAD ligation
In order to further substantiate the promising results 
yielded by SAR1 treatment of permanent LAD ligation, 
we used mass-spectrometry-based quantitative pro-
teomics in order to (1) identify proteome alterations 
associated with the murine permanent LAD ligation and 
(2) monitor the effect of cathepsin A inhibition on those 
proteins that are impacted by permanent LAD ligation 
in the mouse model.
Similar to the section on cardiac functionality, we com-
pared three groups: (1) a sham control group (receiving 
only a left thoracotomy); (2) a placebo-treated MI group 
(MI-placebo); (3) MI group given the cathepsin A inhibi-
tor SAR1 daily starting 1 day after operation (100 mg/kg) 
(MI-SAR1). Left ventricles were harvested 4 weeks after 
sham operation or LAD ligation. A triple labeling strat-
egy was employed [21] with a total of four biological rep-
licates (12 mice in total).
In each of the four replicate experiments we identi-
fied approximately 1300 proteins (Fig. 3a). 1074 proteins 
were identified in at least three replicate experiments and 
we focused on those proteins for further analysis (Addi-
tional file  2). As noticed earlier, partially incomplete 
overlap of proteome coverage is an intrinsic character-
istic of mass—spectrometry based proteomics [22]. Pro-
tein ratios are expressed as fold-change (Fc) values (log2 
of light/heavy, light/medium and heavy/medium ratios). 
All replicates showed a near-normal distribution and an 
average Fc close to zero, indicating that the majority of 
the proteins are not altered (Fig. 3b).
We employed the “significance analysis of microarrays” 
(SAM) method [23] to identify proteins with significantly 
altered abundance in placebo-treated LAD ligation com-
pared to sham operation. At a false discovery rate <1  % 
for significantly affected proteins, we identified 79 pro-
teins as increased in placebo-treated LAD ligation and 25 
proteins as decreased in placebo-treated LAD ligation, in 
comparison to sham operation alone. These proteins are 
summarized in the table included in Additional file 2. This 
“proteomic fingerprint” of permanent LAD ligation com-
prises known marker proteins of cardiac failure. For exam-
ple, we found decreased levels of cardiac troponin T, heart 
fatty acid-binding protein and α-myosin heavy chain as well 
as increased levels of atrial natriuretic peptide, galectin-3 
and several extracellular/matricellular proteins such as per-
iostin, fibulin-1, versican, lumican and osteoglycin (mimi-
can); thereby being in line with earlier reports [24–26].
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Noteworthy, cathepsin A was up-regulated approxi-
mately two-fold in placebo-treated permanent LAD liga-
tion compared to sham-treated animals. This increase 
failed to meet the significance criteria of the SAM 
method. However, a similar increase of cathepsin A levels 
was observed in a rat model of chronic heart failure [6]. 
SAR1 treatment did not change cathepsin A levels in the 
murine hearts upon LAD ligation (Additional file 3).
Next, we assessed the effect of SAR1 treatment on the 
proteomic level. As shown by the scatter plot in Fig.  4a, 
there is a good correlation between proteome alterations 
observed upon placebo-treated LAD ligation (as compared 
to sham operation) and proteome alterations observed upon 
cathepsin A inhibition (as compared to sham operation). 
Simple linear regression yields a positive slope of 0.8, indi-
cating that the overall proteome rearrangement upon LAD 
ligation is similar between placebo and SAR1 treatment 
but that, on average, the extent of quantitative increase or 
decrease is mildly dampened upon cathepsin A inhibition.
We then focused on those proteins that were initially 
found to be significantly affected by the placebo-treated 
LAD ligation (as compared to sham operation). The 
heatmap in Fig. 4b visualizes the effect of SAR1 on this 
Fig. 3 Protein identification and quantification overview for the 
proteome analysis of murine hearts. a Venn diagram representing 
the number of identified proteins in each replicate and their overlap. 
1074 proteins were found in at least three replicates. b Distribution 
and geometric mean (horizontal bar) of fold change values (log2 of 
relative protein ratios) of proteins from the four biological replicates. 
Each replicate contains an animal from each group (sham, MI-pla-
cebo, MI-SAR1)
Fig. 4 Cardiac proteome fingerprint of cathepsin A inhibition upon 
LAD ligation. a Scatter plot and linear regression analysis of protein 
abundance alterations observed for placebo-treated LAD ligation 
(as compared to sham operation) and SAR1-treated LAD ligation 
(as compared to sham operation). b Heatmap comparison of fold 
changes MI-placebo/sham and MI-SAR1/sham of the 104 significantly 
affected proteins upon LAD ligation. Fold changes in the first column 
(MI-placebo/sham) are placed in descending order
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subgroup. It becomes evident that SAR1 treatment par-
tially restores the ligation-induced alterations for many 
proteins in this subgroup. For a more detailed view 
on proteins for which SAR1 rescues, at least in part, a 
ligation-induced alteration, we concentrated on those 
proteins that were (1) significantly affected by placebo-
treated LAD ligation (as compared to sham operation) 
and (2) for which SAR1 treatment increased or decreased 
this effect by more than 50  % (based on averaged pro-
tein ratios from the replicate experiments; difference of 
log2 ratios (MI-placebo/sham)– (MI-SAR1/sham) >0.58). 
These criteria were fulfilled by 21 proteins (Fig. 5a, b). In 
every case, SAR1 treatment dampened the alteration in 
protein abundance that was caused by LAD ligation (as 
compared to sham operation). This effect reached sta-
tistical significance (p  <  0.05, two-sided t-test) for car-
bonic anhydrase 3, Igγ 2b, fatty acid synthase, and Rab-7a 
(attenuated increase in abundance, Fig.  5a) as well as 
cordon-bleu protein-like 1 and perilipin-4 (attenuated 
decrease in abundance, Fig. 5b).
Carbonic anhydrase 3 (CA3) is one of the most up-
regulated proteins upon LAD ligation (~nine-fold 
increase compared to sham operation). Elevated plasma 
levels of CA3 in MI have been previously reported [27, 
Fig. 5 Effect of cathepsin A inhibition on proteome alterations in LAD ligation. a Bar chart depiction of proteins that are significantly increased 
in placebo-treated LAD ligation (as compared to sham operation) and for which SAR1 treatment decreased this effect by a fold-change value of 
more than 50 % [difference of log2 ratios (MI-placebo/sham)–(MI-SAR1/sham) > 0.58]. b Same as (a) but for significantly decreased proteins in LAD 
ligation. Results are expressed as mean ± SEM. Differences significant at p < 0.05 are marked with an asterisk (*). c Western blot analysis of selected 
proteins. Shown here is a representative blot. GAPDH is used as loading control
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28]. Elevated plasma levels of CA3 are also found in 
Duchenne muscular dystrophy [29]. These findings sug-
gest that increased levels of CA3 are associated with 
degenerating or stressed muscle tissue. SAR1 treat-
ment rescued elevated CA3 levels caused by LAD liga-
tion. This was further validated by western blot analysis 
(Fig. 5c).
FAS is a biosynthetic enzyme responsible for de novo 
fatty acid synthesis in mammals. FAS was found to be 
increased in two mechanistically distinct mouse models 
of heart failure and in the hearts of humans with end 
stage cardiomyopathy [30]. We find a more than six-
fold increase of FAS abundance upon placebo-treated 
LAD ligation (as compared to sham operation). In line 
with an increased need for de novo fatty acid synthesis, 
we also noticed reduced levels of perilipin-4, which is 
required for intracellular storage of lipid droplets. In 
both cases, cathepsin A inhibition significantly damp-
ened the altered abundance observed upon placebo-
treated LAD ligation (as compared to sham operation, 
Fig. 5a, b).
Interestingly, we observed that cathepsin A inhibition 
also attenuates elevated levels of cardiac stress response 
proteins, such as periostin, troponin T and cytoglobin. It 
was recently found that cytoglobin expression is strongly 
up-regulated in the hypoxia-induced hypertrophic heart 
[31]. We corroborated the proteomic results observed 
for periostin, troponin T and cytoglobin by immunoblot 
analysis (Fig. 5c; Additional file 4).
In summary, our proteomic results indicate that SAR1 
treatment reduces the extent of cardiac proteome rear-
rangement in permanent LAD ligation.
Effect of cathepsin A inhibition in an in vitro ischemia 
model
The rat cardiomyocyte cell line H9C2 has been previously 
used in cell models of heart ischemia and ischemia–rep-
erfusion [32, 33]. In order to probe a putative cardio-
protective effect of SAR1 in a cell-autonomous system, 
we subjected H9C2 cells to culture conditions of simu-
lated ischemia, which consist of serum deprivation and 
severe hypoxia. After 24 h, we assessed caspase-3 activ-
ity as a marker of apoptosis. SAR1 treatment significantly 
reduced the induction of caspase-3 activity elicited by 
simulated ischemia (Fig.  6a). Flow-cytometry of cells 
stained for the apoptotic marker YO-PRO-1 and the 
necrosis marker PI showed that SAR1 treatment during 
simulated ischemia significantly reduced the percent-
age of cells undergoing apoptosis and, to a lesser extent, 
necrosis (Fig.  6b). Our findings suggest that cathepsin 
A inhibition attenuates ischemia-induced apoptosis in 
H9C2 cells. Additionally, we excluded a hypothetical 
effect of SAR1 on angiogenesis by a matrigel capillary-
like sprouting assay using HUVECs treated with SAR1 
for 16 h (Additional file 5).
Conclusions
The present study suggests that cathepsin A inhibition 
attenuates the impact of MI on the functional and prot-
eomic levels, as probed in a rodent model of permanent 
LAD ligation. For most functional parameters, the effect 
of SAR1 remained a protective trend since statistical 
significance was not fully reached. However, cathepsin 
A inhibition significantly rescued LAD ligation induced 
alterations in abundance for several proteins. Examples 
include plasma BNP and tissue-resident CA3. Since ini-
tial phase 1 studies indicate a favorable safety profile for 
SAR1 [9], our results encourage further investigation in 
cathepsin A inhibition for the treatment of post MI heart 
failure.
Fig. 6 Effect of cathepsin A inhibition in an in vitro model of 
ischemia. Cells were incubated for 24 h with 10 μM SAR1 or DMSO 
as a solvent-only control in simulated ischemia culture conditions 
(hypoxia and serum deprivation, see Methods section for details). 
a Quantitative analysis of caspase-3 activity in the total cell lysate 
of cells treated with SAR1 in standard conditions (normoxia; DMEM 
supplemented with FCS) and simulated ischemia (hypoxia; DMEM 
serum-free). b Cells in simulated ischemia were stained with YO-
PRO-1 or PI and evaluated by flow cytometry. The percentage of cells 
positive to YO-PRO-1 or to PI was calculated. Results are expressed as 
mean ± SEM. Differences significant at p < 0.05 are marked with an 
asterisk (*)
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